Rabeprazole for the treatment of acid-related disorders

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 4, 2012, Pages 423-435

  Marelli, Silvia ^a   Pace, Fabio ^b,c  

^a Janssen Cilag SpA Italia   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c BOLOGNINI HOSPITAL   (Italy)

Author keywords

acid secretion; acid related disorders; gastroesophageal reflux disease; Helicobacter pylori eradication; peptic ulcer disease; proton pump inhibitors; rabeprazole; Zollinger Ellison syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ALFENCE; AMOXICILLIN; ANTACID AGENT; ANTIBIOTIC AGENT; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450 2C19; DIAZEPAM; ESOMEPRAZOLE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; REBAMIPIDE; TICLOPIDINE; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; ATROPHIC GASTRITIS; BLEEDING; CARDIOVASCULAR DISEASE; CELL HYPERPLASIA; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DUODENUM ULCER; ENDOSCOPIC SUBMUCOSAL DISSECTION; ENTERIC COATED TABLET; ENTEROCHROMAFFIN LIKE CELL DYSPLASIA; ENTEROCHROMAFFIN LIKE CELL HYPERPLASIA; ENTEROCHROMAFFIN LIKE CELL NEOPLASM; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; GENOTYPE; HEARTBURN; HELICOBACTER INFECTION; HUMAN; IATROGENIC DISEASE; IATROGENIC ULCER; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON EROSIVE REFLUX DISEASE; OBESITY; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PHARMACODYNAMICS; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; REFLUX ESOPHAGITIS; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; STOMACH ACID SECRETION; STOMACH CANCER; STOMACH PH; STOMACH ULCER; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; ENZYME INHIBITORS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS; ZOLLINGER-ELLISON SYNDROME;

EID: 84865708138     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.18     Document Type: Review

References (83)

1. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem. 272(36), 22438-22446 (1997). (Pubitemid 27386052)
2. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment. Pharmacol. Ther. 17(12), 1507-1514 (2003). (Pubitemid 36831441)
3. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin. Gastroenterol. Hepatol. 5(1), 17-26 (2007). (Pubitemid 46096825)
4. Wahlqvist P, Karlsson M, Johnson D, Carlsson J, Bolge SC, Wallander MA. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment. Pharmacol. Ther. 27(10), 960-970 (2008). (Pubitemid 351537653)
5. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am. J. Gastroenterol. 98(7), 1487-1493 (2003). (Pubitemid 36875337)
6. Dean BB, Crawley JA, Schmitt CM, Wong J, Ofman JJ. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment. Pharmacol. Ther. 17(10), 1309-1317 (2003). (Pubitemid 36693732)
7. Shaheen NJ, Hansen RA, Morgan DR et al. The burden of gastrointestinal and liver diseases, 2006. Am. J. Gastroenterol. 101(9), 2128-2138 (2006). (Pubitemid 44337640)
8. Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics 12(6), 873-888 (2011).
9. Roche VF. The chemically elegant proton pump inhibitors. Am. J. Pharm. Educ. 70(5), 101 (2006).
10. Kromer W, Krüger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 56(2), 57-70 (1998). (Pubitemid 28039688)
11. Sachs G. Improving on PPI-based therapy of GORD. Eur. J. Gastroenterol. Hepatol. 13 (Suppl. 1), S35-S41 (2001).
12. Kirchheiner J, Glatt S, Fuhr U et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur. J. Clin. Pharmacol. 65(1), 19-31 (2009).
13. Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin. Pharmacokinet. 47(1), 1-6 (2008). (Pubitemid 350260884)
14. Swan SK, Hoyumpa AM, Merritt GJ. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment. Pharmacol. Ther. 13 (Suppl. 3), 11-17 (1999). (Pubitemid 29389407)
15. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 57(9), 595-601 (2002). (Pubitemid 35025465)
16. James L, Walson P, Lomax K, Kao R, Varughese S, Reyes J; Study 119 Pediatric Trial Investigators. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study. Clin. Ther. 29(9), 2082-2092 (2007). (Pubitemid 350212802)
17. Yasuda S, Horai Y, Tomono Y et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin. Pharmacol. Ther. 58(2), 143-154 (1995).
18. Tanaka M, Ohkubo T, Otani K et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin. Pharmacol. Ther. 62(6), 619-628 (1997). (Pubitemid 28068065)
19. Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin. Pharmacol. Ther. 61(5), 574-582 (1997). (Pubitemid 27261761)
20. Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs-focus on rabeprazole. J. Gastroenterol. Hepatol. 20 (Suppl.), S22-S28 (2005).
21. McColl KE, Kennerley P. Proton pump inhibitors-differences emerge in hepatic metabolism. Dig. Liver Dis. 34(7), 461-467 (2002). (Pubitemid 34830685)
22. Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors - focus on pKa and metabolism. Aliment. Pharmacol. Ther. Symp. 2, 340-350 (2006).
23. Adachi K, Katsube T, Kawamura A et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment. Pharmacol. Ther. 14(10), 1259-1266 (2000).
24. Ariizumi K, Ohara S, Koike T et al. Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. J. Gastroenterol. Hepatol. 21(9), 1428-1434 (2006). (Pubitemid 44154712)
25. Ando T, Kato H, Sugimoto N et al. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig. Dis. Sci. 50(9), 1625-1631 (2005). (Pubitemid 41203654)
26. Kawabata H, Habu Y, Tomioka H et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment. Pharmacol. Ther. 17(2), 259-264 (2003). (Pubitemid 36174257)
27. Furuta T, Shirai N, Watanabe F et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin. Pharmacol. Ther. 72(4), 453-460 (2002). (Pubitemid 35178870)
28. Kuo CH, Wang SS, Hsu WH et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter 15(4), 265-272 (2010).
29. Kodaira C, Uchida S, Yamade M et al. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test. J. Clin. Pharmacol. 52(3), 432-439 (2012).
30. Robinson M, Barone J. Review article: comparative pharmacodynamic review of rabeprazole - focus on day 1 data. Aliment. Pharmacol. Ther. Symp. Ser. 2, 315-326 (2006).
31. Adachi K, Hashimoto T, Hamamoto N et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J. Gastroenterol. Hepatol. 18(12), 1392-1398 (2003). (Pubitemid 38045853)
32. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L; FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment. Pharmacol. Ther. 16(3), 445-454 (2002). (Pubitemid 34214523)
33. Eggleston A, Katelaris PH, Nandurkar S, Thorpe P, Holtmann G; Treat Study Group. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care-prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment. Pharmacol. Ther. 29(9), 967-978 (2009).
34. El-Serag H. Role of obesity in GORD-related disorders. Gut 57(3), 281-284 (2008). (Pubitemid 351288088)
35. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 101(8), 1900-20; quiz 1943 (2006).
36. Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Rev. Gastroenterol. Hepatol. 2(4), 509-522 (2008).
37. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J. Clin. Gastroenterol. 41(2), 131-137 (2007). (Pubitemid 46148652)
38. Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment. Pharmacol. Ther. 33(2), 213-224 (2011).
39. Ashida K, Kinoshita Y, Hongo M; Japan Rabeprazole Study Group for NERD. Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study. Dig. Dis. Sci. 56(8), 2333-2342 (2011).
40. Savarino E, Marabotto E, Zentilin P et al. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig. Liver Dis. 43(7), 542-547 (2011).
41. Kusano M, Shirai N, Yamaguchi K, Hongo M, Chiba T, Kinoshita Y; Acid-Related Symptom (ARS) Research Group. It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole - a report from a study with Japanese patients. Dig. Dis. Sci. 53(12), 3082-3094 (2008).
42. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment. Pharmacol. Ther. 24(5), 743-750 (2006).
43. Cutler A, Robinson M, Murthy A, Delemos B. Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results. Dig. Dis. Sci. 55(2), 338-345 (2010).
44. Saitoh T, Otsuka H, Kawasaki T et al. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. Hepatogastroenterology 56(91-92), 703-706 (2009).
45. Carlsson R, Dent J, Bolling-Sternevald E et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand. J. Gastroenterol. 33(10), 1023-1029 (1998). (Pubitemid 28505643)
46. Dubois RW, Aguilar D, Fass R et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. Aliment. Pharmacol. Ther. 25(4), 487-500 (2007). (Pubitemid 46184463)
47. Orr WC, Heading R, Johnson LF, Kryger M. Review article: sleep and its relationship to gastro-oesophageal reflux. Aliment. Pharmacol. Ther. 20 (Suppl. 9), 39-46 (2004). (Pubitemid 39657653)
48. Fujiwara Y, Kohata Y, Kaji M et al. Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole. Digestion 81(3), 135-141 (2010).
49. Orr WC, Robert JJ, Houck JR, Giddens CL, Tawk MM. The effect of acid suppression on upper airway anatomy and obstruction in patients with sleep apnea and gastroesophageal reflux disease. J. Clin. Sleep Med. 5(4), 330-334 (2009).
50. Shaheen NJ, Madanick RD, Alattar M et al. Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: a pilot study of prevalence and response to therapy. Dig. Dis. Sci. 53(6), 1493-1499 (2008).
51. Jacobson BC, DeLemos B, Sun Y et al. PPI Efficacy in overweight/obese patients with erosive GERD: rabeprazole (RAB) 20 mg vs. omeprazole (OME) 20 mg. Am. J. Gastroenterol 102 (Suppl. 2), S150 (2007).
52. Pace F, Coudsy B, DeLemos B et al. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. Eur. J. Gastroenterol. Hepatol. 23(10), 845-851 (2011).
53. Furuta T, Shimatani T, Sugimoto M et al. The Acid-Related Symptom Research Group. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs- TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J. Gastroenterol. 46(11), 1273-1283 (2011).
54. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56(6), 772-781 (2007). (Pubitemid 46854190)
55. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int. J. Clin. Pharmacol. Ther. 44(7), 297-302 (2006). (Pubitemid 44043771)
56. Hartland S, Newton JL, Griffin SM, Donaldson PT. A functional polymorphism in the interleukin-1 receptor-1 gene is associated with increased risk of Helicobacter pylori infection but not with gastric cancer. Dig. Dis. Sci. 49(9), 1545-1550 (2004). (Pubitemid 39273638)
57. Zhang L, Mei Q, Li QS, Hu YM, Xu JM. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. J. Clin. Pharm. Ther. 35(6), 713-722 (2010).
58. Javid G, Zargar SA, U-Saif R et al. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. J. Gastroenterol. Hepatol. 24(7), 1236-1243 (2009).
59. Awtry EH, Loscalzo J. Aspirin. Circulation 101(10), 1206-1218 (2000). (Pubitemid 30146625)
60. Patrono C, Bachmann F, Baigent C et al.; European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur. Heart J. 25(2), 166-181 (2004). (Pubitemid 38112156)
61. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sáinz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment. Pharmacol. Ther. 16(4), 779-786 (2002). (Pubitemid 34407526)
62. Liberopoulos EN, Elisaf MS, Tselepis AD et al. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now? Platelets 17(1), 1-6 (2006). (Pubitemid 41759234)
63. Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 352(3), 238-244 (2005). (Pubitemid 40110812)
64. Luo JC, Huang KW, Leu HB et al. Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirinrelated peptic ulcer. Aliment. Pharmacol. Ther. 34(5), 519-525 (2011).
65. Kakushima N, Yahagi N, Fujishiro M et al. The healing of gastric ulcers after endoscopic submucosal dissection. J. Dig. Endosc. 16, 327-331 (2004). (Pubitemid 39421399)
66. Fujiwara S, Morita Y, Toyonaga T, Itoh T, Yoshida M, Kutsumi H. Rebamipide combined with PPI enhances the healing process of post-ESD ulcer; a randomized prospective study. Gastrointest. Endosc. 69(5), AB178 (2009).
67. Fujiwara S, Morita Y, Toyonaga T et al. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J. Gastroenterol. 46(5), 595-602 (2011).
68. Fujimoto K, Hongo M; Maintenance Study Group. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis. Intern. Med. 50(3), 179-188 (2011).
69. Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B; European Rabeprazole Study Group. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur. J. Gastroenterol. Hepatol. 17(5), 559-566 (2005). (Pubitemid 40592714)
70. Salgueiro E, Rubio T, Hidalgo A, Manso G. Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions. Int. J. Clin. Pharmacol. Ther. 44(11), 548-556 (2006). (Pubitemid 44718190)
71. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment. Pharmacol. Ther. 13 (Suppl. 3), 27-36 (1999). (Pubitemid 29389409)
72. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment. Pharmacol. Ther. 13 (Suppl. 3), 18-26 (1999). (Pubitemid 29389408)
73. Hata M, Hayasaka M, Sezai A et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac. Cardiovasc. Surg. 56(5), 274-277 (2008).
74. Coudsy B, Funck-Brentano C, Blanchard A et al. Effect of rabeprazole on the antiplatelet action of clopidogrel, a prospective, randomized, 3-way crossover PK/PD study in healthy subjects. Gut 60(Suppl. 3), A264 (2011).
75. Sharara A, Malli A, El-Halabi M et al. The effect of CYP2C19 genetic polymorphisms and the concomitant use of rabeprazole or esomeprazole on the antiplatelet action of clopidogrel. Am. J. Gastroenterol. 106(2), S37-S38 (2011).
76. Kinoshita Y, Matsumoto N, Watanabe M et al. Comparison of the effects of omeprazole and rabeprazole on ticlopidine metabolism in vitro. J. Pharmacol. Sci. 117(1), 19-26 (2011).
77. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51(3), 256-260 (2008).
78. Fernando H, Bassler N, Habersberger J et al. Randomized double-blind placebocontrolled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J. Thromb. Haemost. 9(8), 1582-1589 (2011).
79. Bhatt DL, Cryer BL, Contant CF et al.; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363(20), 1909-1917 (2010).
80. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebocontrolled, crossover comparison studies. Clin. Pharmacol. Ther. 89(1), 65-74 (2011).
81. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin. Gastroenterol. Hepatol. 4(12), 1452-1458 (2006). (Pubitemid 44895413)
82. Sheu BS, Cheng HC, Chang WL, Chen WY, Kao AW. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am. J. Gastroenterol. 102(11), 2387-2394 (2007).
83. Sheu BS, Chang WL, Cheng HC, Kao AW, Lu CC. Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole. Am. J. Gastroenterol. 103(9), 2209-2214 (2008).